Articoli con mandati relativi all'accesso pubblico - James BradnerUlteriori informazioni
TotaleNIHDamon Runyon Cancer Research FoundationHHMIWellcomeDFGDoDCancer Research UKNSFCIHRFWFSNSFEuropean CommissionINSERMSwedish Research CouncilNHMRCGenome CanadaCPRITDOEEMBLLymphoma Research Foundation, USAV Foundation, USASusan G. KomenMRCWorldwide Cancer Research, UKKWFNMRCNational Research Foundation, SingaporeAHANSERCNSFCEPSRCDoris Duke Charitable FoundationGovernment of SpainFondazione AIRC per la Ricerca sul CancroJDRFCarlsberg Foundation DKHFSPFordVAMacArthurARCFWOHelmholtzDFFHRBSFIDSTWellcome Trust/DBT India AllianceNWOBBSRCBreast Cancer Now, UKNIHRIRCBMBFSCLGoverno ItalianoChildren's Tumor Foundation, USAAlex's Lemonade StandRoyal Society UK
Non disponibili pubblicamente: 3
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
T De Raedt, E Beert, E Pasmant, A Luscan, H Brems, N Ortonne, K Helin, ...
Nature 514 (7521), 247-251, 2014
Mandati: US National Institutes of Health, Research Foundation (Flanders), National …
Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders
M Ishoey, S Chorn, N Singh, MG Jaeger, M Brand, J Paulk, S Bauer, ...
ACS Chemical Biology 13 (3), 553-560, 2018
Mandati: US National Institutes of Health, Carlsberg Foundation DK
A chemical probe toolbox for dissecting the cancer epigenome
J Shortt, CJ Ott, RW Johnstone, JE Bradner
Nature Reviews Cancer 17 (3), 160-183, 2017
Mandati: US National Institutes of Health, National Health and Medical Research …
Disponibili pubblicamente: 247
Selective inhibition of BET bromodomains
P Filippakopoulos, J Qi, S Picaud, Y Shen, WB Smith, O Fedorov, ...
Nature 468 (7327), 1067-1073, 2010
Mandati: US National Institutes of Health, Canadian Institutes of Health Research …
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
JE Delmore, GC Issa, ME Lemieux, PB Rahl, J Shi, HM Jacobs, E Kastritis, ...
Cell 146 (6), 904-917, 2011
Mandati: US National Institutes of Health
Selective inhibition of tumor oncogenes by disruption of super-enhancers
J Lovén, HA Hoke, CY Lin, A Lau, DA Orlando, CR Vakoc, JE Bradner, ...
Cell 153 (2), 320-334, 2013
Mandati: US National Institutes of Health, Swedish Research Council
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
J Zuber, J Shi, E Wang, AR Rappaport, H Herrmann, EA Sison, D Magoon, ...
Nature 478 (7370), 524-528, 2011
Mandati: US National Institutes of Health, Howard Hughes Medical Institute, German …
HDAC2 negatively regulates memory formation and synaptic plasticity
JS Guan, SJ Haggarty, E Giacometti, JH Dannenberg, N Joseph, J Gao, ...
Nature 459 (7243), 55-60, 2009
Mandati: US National Institutes of Health, Howard Hughes Medical Institute
Transcriptional amplification in tumor cells with elevated c-Myc
CY Lin, J Lovén, PB Rahl, RM Paranal, CB Burge, JE Bradner, TI Lee, ...
Cell 151 (1), 56-67, 2012
Mandati: US National Institutes of Health, Swedish Research Council
Phthalimide conjugation as a strategy for in vivo target protein degradation
GE Winter, DL Buckley, J Paulk, JM Roberts, A Souza, S Dhe-Paganon, ...
Science 348 (6241), 1376-1381, 2015
Mandati: US National Institutes of Health, John D. and Catherine T. MacArthur …
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins
G Lu, RE Middleton, H Sun, MV Naniong, CJ Ott, CS Mitsiades, KK Wong, ...
Science 343 (6168), 305-309, 2014
Mandati: US National Institutes of Health, Howard Hughes Medical Institute, German …
Transcriptional addiction in cancer
JE Bradner, D Hnisz, RA Young
Cell 168 (4), 629-643, 2017
Mandati: US National Institutes of Health, Austrian Science Fund
R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling
R Su, L Dong, C Li, S Nachtergaele, M Wunderlich, Y Qing, X Deng, ...
Cell 172 (1), 90-105. e23, 2018
Mandati: US National Institutes of Health, Howard Hughes Medical Institute, Damon …
Direct inhibition of the NOTCH transcription factor complex
RE Moellering, M Cornejo, TN Davis, CD Bianco, JC Aster, SC Blacklow, ...
Nature 462 (7270), 182-188, 2009
Mandati: US National Institutes of Health
YY1 is a structural regulator of enhancer-promoter loops
AS Weintraub, CH Li, AV Zamudio, AA Sigova, NM Hannett, DS Day, ...
Cell 171 (7), 1573-1588. e28, 2017
Mandati: US National Science Foundation, US National Institutes of Health, Damon …
Chemical phylogenetics of histone deacetylases
JE Bradner, N West, ML Grachan, EF Greenberg, SJ Haggarty, T Warnow, ...
Nature chemical biology 6 (3), 238-243, 2010
Mandati: US National Institutes of Health
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma
B Chapuy, MR McKeown, CY Lin, S Monti, MGM Roemer, J Qi, PB Rahl, ...
Cancer cell 24 (6), 777-790, 2013
Mandati: US National Institutes of Health, German Research Foundation
The dTAG system for immediate and target-specific protein degradation
B Nabet, JM Roberts, DL Buckley, J Paulk, S Dastjerdi, A Yang, ...
Nature chemical biology 14 (5), 431-441, 2018
Mandati: US National Institutes of Health, Damon Runyon Cancer Research Foundation
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
S Gröschel, MA Sanders, R Hoogenboezem, E de Wit, BAM Bouwman, ...
Cell 157 (2), 369-381, 2014
Mandati: German Research Foundation, Worldwide Cancer Research, UK
Targeting MYCN in neuroblastoma by BET bromodomain inhibition
A Puissant, SM Frumm, G Alexe, CF Bassil, J Qi, YH Chanthery, ...
Cancer discovery 3 (3), 308-323, 2013
Mandati: US National Institutes of Health, Howard Hughes Medical Institute
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software